Late breaker presentation of long-term analysis of Phase 2 INDIGO study shows sustained response and clinically-relevant growth accelerations in PFIC2 responders Data from Phase 2b ICONIC study show profound and durable improvements in itch severity and serum bile acids in children with Alagille

Maralixibat shows reductions in pruritus and serum bile acids in 48 week analysis of ICONIC Phase 2b study in Alagille syndrome patients Long-term analysis of INDIGO study of maralixibat shows sustained response and growth improvements in progressive familial intrahepatic cholestasis type two

Mike Grey to Remain with Mirum in Role of Executive Chairman FOSTER CITY, Calif. , March 21, 2019 /PRNewswire/ -- Mirum Pharmaceuticals today announced the appointment of Chris Peetz as chief executive officer. The company's former CEO, Mike Grey , will stay on with Mirum in the role of executive